Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States.…
USD328.13+1.04%vs prev. close
Performance
1W
+23.68%
1M
+33.46%
3M
-11.86%
1Y
+76.87%
YTD
+10.19%
Valuation
P/E
—
EPS TTM
-12.93
Dividend yield
—
Size and risk
Market cap
$9.2B
Beta
2.84
Price history
PRAX price
USD
Total returnEventsVs index
Loading…
Next earnings
Report date
EPS estimate
Revenue estimate
Peer comparison
Praxis Precision Medicines
PRAX
Biotechnology
Mkt cap (USD bn)
9.2
P/E
—
Div yld
—
1W
+23.7%
1M
+33.5%
3M
-11.9%
6M
-6.0%
1Y
+76.9%
YTD
+10.2%
Company
Ticker
Industry
Mkt cap (USD bn)
P/E
Div yld
1W
1M
3M
6M
1Y
YTD
Praxis Precision Medicines
PRAX
Biotechnology
9.2
—
—
+23.7%
+33.5%
-11.9%
-6.0%
+76.9%
+10.2%
Subscribe to Equity Analytics to compare PRAX with its closest peers
Sector-matched peer set with side-by-side valuation, dividend and performance over every window.